Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver C Cohen

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Leukemia|April 10, 2020
Systemic amyloidosis: moving into the spotlightOliver C Cohen, Ashutosh D Wechalekar
European Journal of Haematology|November 7, 2020
Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real-World Experience from 554 sequential core biopsies from a single centreOliver C Cohen, Maximillian H Brodermann, Aoife Dervin, et al.
British Journal of Haematology|June 30, 2021
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal dataSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
European Journal of Haematology|June 5, 2020
The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosisOliver C Cohen, Faye Sharpley, Janet A Gilbertson, et al.
Blood Cancer Journal|June 22, 2021
Impact of early response on outcomes in AL amyloidosis following treatment with frontline BortezomibSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
Blood Cancer Journal|May 24, 2020
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosisOliver C Cohen, Steven Law, Helen J Lachmann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 22, 2021
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single-centre experienceOliver C Cohen, Michele Bertelli, Gavin Manmathan, et al.
ESC Heart Failure|September 14, 2020
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stageSteven Law, Aviva Petrie, Liza Chacko, et al.
Heart (British Cardiac Society)|May 15, 2021
Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathySteven Law, Aviva Petrie, Liza Chacko, et al.
British Journal of Haematology|November 22, 2018
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapseOliver C Cohen, Nicholas Counsell, Neil Rabin, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Leukemia|April 10, 2020
Systemic amyloidosis: moving into the spotlightOliver C Cohen, Ashutosh D Wechalekar
European Journal of Haematology|November 7, 2020
Lymph node core biopsies reliably permit diagnosis of lymphoproliferative diseases. Real-World Experience from 554 sequential core biopsies from a single centreOliver C Cohen, Maximillian H Brodermann, Aoife Dervin, et al.
British Journal of Haematology|June 30, 2021
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal dataSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
European Journal of Haematology|June 5, 2020
The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosisOliver C Cohen, Faye Sharpley, Janet A Gilbertson, et al.
Blood Cancer Journal|June 22, 2021
Impact of early response on outcomes in AL amyloidosis following treatment with frontline BortezomibSriram Ravichandran, Oliver C Cohen, Steven Law, et al.
Blood Cancer Journal|May 24, 2020
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosisOliver C Cohen, Steven Law, Helen J Lachmann, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 22, 2021
Challenges of antithrombotic therapy in the management of cardiovascular disease in patients with inherited bleeding disorders: A single-centre experienceOliver C Cohen, Michele Bertelli, Gavin Manmathan, et al.
ESC Heart Failure|September 14, 2020
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stageSteven Law, Aviva Petrie, Liza Chacko, et al.
Heart (British Cardiac Society)|May 15, 2021
Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathySteven Law, Aviva Petrie, Liza Chacko, et al.
British Journal of Haematology|November 22, 2018
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapseOliver C Cohen, Nicholas Counsell, Neil Rabin, et al.
Pageof 2